» Articles » PMID: 26231844

Increased Heme Levels in the Heart Lead to Exacerbated Ischemic Injury

Overview
Date 2015 Aug 2
PMID 26231844
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Heme is an essential iron-containing molecule for cardiovascular physiology, but in excess it may increase oxidative stress. Failing human hearts have increased heme levels, with upregulation of the rate-limiting enzyme in heme synthesis, δ-aminolevulinic acid synthase 2 (ALAS2), which is normally not expressed in cardiomyocytes. We hypothesized that increased heme accumulation (through cardiac overexpression of ALAS2) leads to increased oxidative stress and cell death in the heart.

Methods And Results: We first showed that ALAS2 and heme levels are increased in the hearts of mice subjected to coronary ligation. To determine the causative role of increased heme in the development of heart failure, we generated transgenic mice with cardiac-specific overexpression of ALAS2. While ALAS2 transgenic mice have normal cardiac function at baseline, their hearts display increased heme content, higher oxidative stress, exacerbated cell death, and worsened cardiac function after coronary ligation compared to nontransgenic littermates. We confirmed in cultured cardiomyoblasts that the increased oxidative stress and cell death observed with ALAS2 overexpression is mediated by increased heme accumulation. Furthermore, knockdown of ALAS2 in cultured cardiomyoblasts exposed to hypoxia reversed the increases in heme content and cell death. Administration of the mitochondrial antioxidant MitoTempo to ALAS2-overexpressing cardiomyoblasts normalized the elevated oxidative stress and cell death levels to baseline, indicating that the effects of increased ALAS2 and heme are through elevated mitochondrial oxidative stress. The clinical relevance of these findings was supported by the finding of increased ALAS2 induction and heme accumulation in failing human hearts from patients with ischemic cardiomyopathy compared to nonischemic cardiomyopathy.

Conclusions: Heme accumulation is detrimental to cardiac function under ischemic conditions, and reducing heme in the heart may be a novel approach for protection against the development of heart failure.

Citing Articles

β-blockers and metabolic modulation: unraveling the complex interplay with glucose metabolism, inflammation and oxidative stress.

Drygala S, Radzikowski M, Maciejczyk M Front Pharmacol. 2025; 15:1489657.

PMID: 39759452 PMC: 11695285. DOI: 10.3389/fphar.2024.1489657.


25-Hydroxycholecalciferol Improves Cardiac Metabolic Adaption, Mitochondrial Biogenetics, and Redox Status to Ameliorate Pathological Remodeling and Functional Failure in Obese Chickens.

Chiang S, Sin M, Lin J, Siregar M, Valdez G, Chen Y Antioxidants (Basel). 2024; 13(11).

PMID: 39594567 PMC: 11590958. DOI: 10.3390/antiox13111426.


IL-6 inhibition prevents costimulation blockade-resistant allograft rejection in T cell-depleted recipients by promoting intragraft immune regulation in mice.

Muckenhuber M, Mengrelis K, Weijler A, Steiner R, Kainz V, Buresch M Nat Commun. 2024; 15(1):4309.

PMID: 38830846 PMC: 11148062. DOI: 10.1038/s41467-024-48574-w.


overexpression alleviates oxidative stress-induced ferroptosis in aortic aneurysms via activation.

He Y, Wang X, Li D, Zhu Q, Xiang Y, He Y J Thorac Dis. 2024; 16(4):2510-2527.

PMID: 38738239 PMC: 11087628. DOI: 10.21037/jtd-24-370.


Targeting Ferroptosis: A Novel Strategy for the Treatment of Atherosclerosis.

Zhang Y, Jiang C, Meng N Mini Rev Med Chem. 2024; 24(13):1262-1276.

PMID: 38284727 DOI: 10.2174/0113895575273164231130070920.


References
1.
Meneghini R . Iron homeostasis, oxidative stress, and DNA damage. Free Radic Biol Med. 1997; 23(5):783-92. DOI: 10.1016/s0891-5849(97)00016-6. View

2.
Poulos T . Heme enzyme structure and function. Chem Rev. 2014; 114(7):3919-62. PMC: 3981943. DOI: 10.1021/cr400415k. View

3.
Sadlon T, DellOso T, Surinya K, May B . Regulation of erythroid 5-aminolevulinate synthase expression during erythropoiesis. Int J Biochem Cell Biol. 1999; 31(10):1153-67. DOI: 10.1016/s1357-2725(99)00073-4. View

4.
Bayeva M, Sawicki K, Butler J, Gheorghiade M, Ardehali H . Molecular and cellular basis of viable dysfunctional myocardium. Circ Heart Fail. 2014; 7(4):680-91. PMC: 4104430. DOI: 10.1161/CIRCHEARTFAILURE.113.000912. View

5.
Takaku F, Yano Y, Aoki Y, Nakao K, Wada O . -Aminolevulinic acid synthetase activity of human bone marrow erythroid cells in various hematological disorders. Tohoku J Exp Med. 1972; 107(3):217-28. DOI: 10.1620/tjem.107.217. View